Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group

Gastroenterology
J R GreenM D Taylor

Abstract

Aminosalicylates are widely used in the treatment of ulcerative colitis (UC). Balsalazide is a novel mesalamine prodrug, activated by colonic bacteria. The aim of this study was to compare the efficacy and safety of balsalazide with that of a pH-dependent formulation of mesalamine in active UC. A randomized, double-blind study was performed comparing balasalazide, 6.75 g daily, with mesalamine, 2.4 g daily, administered for 4, 8, or 12 weeks to 101 (99 evaluable) patients with symptomatic, sigmoidoscopically verified UC. More patients treated with balsalazide achieved symptomatic remission after 2 (64% [balsalazide] vs. 43% [mesalamine]), 4 (70% vs. 51%), 8 (78% vs. 45%), and 12 weeks (88% vs. 57%) and complete remission (none/mild symptoms, sigmoidoscopy grade 0/1, no rectal steroid use within 4 days) after 4 (38% vs. 12%), 8 (54% vs. 22%), and 12 weeks (62% vs. 37%). Patients taking balsalazide experienced more asymptomatic days (4 weeks, 24% vs. 14%) and achieved the first asymptomatic day more rapidly (median, 10 vs. 25 days). Fewer patients in the balsalazide group reported adverse events (48% vs. 71%); four serious adverse events occurred in the mesalamine group. Balsalazide is more effective and better tolerated than mes...Continue Reading

References

Sep 1, 1992·British Journal of Clinical Pharmacology·B Crotty, D P Jewell
Jul 4, 1992·BMJ : British Medical Journal·M A Kamm, A Senapati
Sep 1, 1982·British Journal of Clinical Pharmacology·M J DewJ Rhodes
Mar 28, 1996·The New England Journal of Medicine·S B Hanauer

❮ Previous
Next ❯

Citations

Aug 2, 2008·Inflammatory Bowel Diseases·Michael A KammRaymond Joseph
Sep 17, 2009·Digestive Diseases and Sciences·Jonathan P TerdimanKenneth R McQuaid
Nov 6, 2004·Current Gastroenterology Reports·Andrew S Ross, Russell D Cohen
Sep 21, 2001·Alimentary Pharmacology & Therapeutics·K Ragunath, J G Williams
Feb 1, 2004·Clinics in Colon and Rectal Surgery·Uma Mahadevan
Aug 9, 2002·The New England Journal of Medicine·Daniel K Podolsky
Oct 7, 2006·Current Opinion in Gastroenterology·C J Ooi, B E Sands
Mar 22, 2002·Journal of Clinical Gastroenterology·Seymour Katz
Jan 28, 2005·Inflammatory Bowel Diseases·Seong Won HanMark Richard Welfare
Sep 29, 2005·Inflammatory Bowel Diseases·Carmen CuffariGary R Lichtenstein
Apr 15, 2003·Gut·J C Mansfield
Oct 18, 2005·Drugs·Steven MassonJohn C Mansfield
May 20, 2008·Drugs·Nielsen Q Fernandez-Becker, Alan C Moss
Jul 5, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·S Ishaq, J R Green
Oct 14, 2006·Paediatric Drugs·Paul A Rufo, Athos Bousvaros
Jan 18, 2008·World Journal of Gastroenterology : WJG·Patricia L Kozuch, Stephen B Hanauer
Mar 1, 2008·Journal of Crohn's & Colitis·S P L TravisUNKNOWN European Crohn's and Colitis Organisation (ECCO)
Aug 28, 2009·Expert Opinion on Drug Metabolism & Toxicology·Antonio Tursi
Nov 30, 2011·Best Practice & Research. Clinical Gastroenterology·Christoph Campregher, Christoph Gasche
Oct 19, 2010·Gastroenterology Clinics of North America·Irene SonuGary R Lichtenstein
Jun 15, 2007·The Surgical Clinics of North America·Cyrus P Tamboli
Jan 24, 2007·Gastroenterology·Stefan SchreiberStephen B Hanauer
Sep 13, 2003·British Journal of Clinical Pharmacology·E Carty, D S Rampton
Nov 9, 2010·Journal of the American Academy of Nurse Practitioners·Jill Olmstead
Nov 24, 2004·Advanced Drug Delivery Reviews·Altamash I Qureshi, Russell D Cohen
Jan 24, 2007·Gastroenterology·Michael A KammRaymond E Joseph
Jun 5, 2004·Gastroenterology Clinics of North America·Douglas B Haghighi, Bret A Lashner
Jun 5, 2004·Gastroenterology Clinics of North America·Laura E Harrell, Stephen B Hanauer
Jun 5, 2004·Gastroenterology Clinics of North America·Craig A Solem, Edward V Loftus
Feb 23, 2008·Internal Medicine Journal·S L JamesP R Gibson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.